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ABSTRACT  
 
Objective. To examine the natural course of social anxiety disorder (SAD) in the community 
and to explore predictors for adverse long-term outcomes. 
Method. A community sample of N=3,021 subjects aged 14-24 was followed-up over 10 
years using the DSM-IV/M-CIDI. Persistence of SAD is based on a composite score 
reflecting the proportion of years affected since onset. Diagnostic stability is the proportion of 
SAD subjects still affected at follow-up.  
Results. SAD reveals considerable persistence with more than half of the years observed 
since onset spent with symptoms. 56.7% of SAD cases revealed stability with at least 
symptomatic expressions at follow-up; 15.5% met SAD threshold criteria again. 15.1% were 
completely remitted (no SAD symptoms and no other mental disorders during follow-up). 
Several clinical features (early onset, generalized subtype, more anxiety cognitions, severe 
avoidance and impairment, co-occurring panic) and vulnerability characteristics (parental 
SAD and depression, behavioural inhibition, harm avoidance) predicted higher SAD 
persistence and -less impressively- diagnostic stability.  
Conclusion. A persistent course with a considerable degree of fluctuations in symptom 
severity is characteristic for SAD. Both, consistently meeting full threshold diagnostic criteria 
and complete remissions are rare. Vulnerability and clinical severity indicators predict poor 
prognosis and might be helpful markers for intervention needs. 
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Significant outcomes:  
(1) Diagnostic stability of SAD above the DSM-IV threshold level over long periods of time 
but also complete remissions (neither SAD symptoms nor other psychopathology) are rare. 
SAD has considerable persistence considering subthreshold and symptomatic expressions.  
(2) Isolated fears of exams/tests in adolescence have the lowest persistence, whereas 
generalized and early onset social fears show the highest persistence and stability.  
(3) Symptom complexity and severity as measured with SAD diagnostic criteria as well as 
co-occurring conditions are important clinical characteristics that predict a persistent and 
stable course of SAD, suggesting that this diagnostic information is useful and practical to 
inform about prognosis and need for intervention. 
 
Limitations: 
(1) Stability and persistence estimates were based on up to four symptom and diagnostic 
assessments conducted with standardized diagnostic interview (DIA-X/M-CIDI) across a time 
period of up to ten years. Assessments did not include specific questions on course patterns 
of SAD, which impedes the differentiation of recurrence vs. chronicity. 
(2) Stability and persistence estimates are conservative given that maximum age of 
respondents was 34 years at last follow-up and given that some SAD cases had short follow-
up periods.  
(3) Despite the prospective-longitudinal design of the study, data are based on retrospective 
recall and thus are subject to bias which may particularly have influenced the persistence 
measure. 
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INTRODUCTION 
Social anxiety disorder (SAD) is a prevalent mental disorder with an estimated mean 
lifetime prevalence of 6.7% (range 3.9-13.7%) in European countries (1), and rates up to 
12.1% in US community studies (2, 3). SAD typically has its onset in adolescence (2-9) and 
is associated with high comorbidity (1, 3-5, 9-12), substantial impairment and disability in 
psychosocial functioning (4, 11-15). 
Relatively little is known about the natural course of the disorder which can be 
described in terms of (1) persistence and (2) diagnostic stability versus spontaneous 
remission. Retrospective cross-sectional and clinical data predominantly from adults indicate 
that SAD is highly persistent, with duration estimates of 10 years and longer (4, 5, 8, 12, 16-
22). These findings suggest a stable and unremitting course of the condition. In contrast, 
longitudinal community studies that allow prospective examinations of diagnostic stability and 
spontaneous remission suggest a waxing and waning course of SAD with frequent 
oscillations around the DSM-IV diagnostic threshold (7, 8, 23). These studies were largely 
based on non-adult samples. Spontaneous remissions from SAD have also been reported 
(24-29). Empirical evidence for complete remission, i.e. the absence of any psychopathology, 
however, is rare (24, 25). No prior study has used a longitudinal approach to study the 
natural course of SAD both in terms of persistence and in terms of diagnostic stability and 
spontaneous remission. Conducting such a study during the high risk period for onset and 
potential subsequent chronicity of SAD would be particularly important to advancing our 
understanding of SAD prognosis and treatment interventions. Given prior findings on 
disability, psychosocial functioning, comorbidity, economic costs, partial recoveries or 
symptom fluctuation, consideration of subthreshold SAD appears particularly critical (5, 30, 
31) as is the additional differentiation of even milder, symptomatic social fear expressions (5, 
7, 29, 32).  
Even less is known about the predictors for persistence and diagnostic stability of 
SAD and to what degree they differ from established vulnerability and risk factors for initial 
SAD onset. Several studies have documented associations between parental 
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psychopathology (33-35), temperamental and personality characteristics (36-39), as well as 
psychopathological risk factors such as panic attacks (40) and SAD, suggesting relevance 
for disorder onset. Few studies have examined whether such variables also predict high 
persistence and stable course of SAD. One recent study found that lack of emotional warmth 
and dysfunctional family functioning characteristics were associated with higher SAD 
persistence, particularly in interaction with parental psychopathology (41). With regard to 
clinical characteristics as predictors of course, many studies merely refer to anxiety disorders 
in general, with early age of onset (42), degree of impairment (43), or comorbidities (17-19) 
being associated with an unfavourable outcome. The few available SAD studies yield 
heterogeneous findings: whereas one 1.5 year follow-up study in young women did not find 
any disorder characteristics such as severity or duration of symptoms as predictors (29), 
other studies with partially longer follow-up periods and including both genders reported that 
baseline severity (44), symptom duration and comorbid panic disorder (22) were related to 
poor outcomes of SAD.  
Overall, conclusions on the natural course of SAD and its predictors are limited to 
heterogeneous findings. Studies often differ in terms of their design (cross-sectional vs. 
longitudinal), time period, and selected SAD-related characteristics and risk factors. Using 
data from a representative community sample of adolescents and young adults followed 
prospectively over 10 years, which covers the high risk period for initial SAD onset and 
potential sequelae, we previously described the incidence patterns of SAD and subsequent 
onset of depression (9, 45), risk factors for the onset of SAD (34, 46), predictors for the onset 
of subsequent depression (9, 47), as well as select familial risk factors for persistence of 
SAD (41). The current study aims to use these data to describe in greater detail the natural 
course of SAD. 
 
Aims of the study 
The aims of the current study are: 
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(1) to provide a comprehensive description of the natural course of DSM-IV SAD both 
in terms of persistence and in terms of diagnostic stability and remission, following a 
longitudinal approach that takes into account different diagnostic threshold levels and 
comorbid conditions, and 
(2) to examine a range of distal and proximal predictors for an unfavourable course 
(high persistence and stability versus remission) of SAD symptoms after initial threshold SAD 
onset.  
 
MATERIAL AND METHODS 
The prospective longitudinal Early Developmental Stages of Psychopathology 
(EDSP) study assessed mental disorders and associated risk factors in a representative 
sample of N=3,021 adolescents and young adults aged 14-24 years at baseline (T0). The 
study also includes follow-up surveys (T1/T2/T3), a family history component (T0/T2/T3) and 
direct assessments of parents (T1/T3). Methods, design and information on 
representativeness and response rates have been previously reported (48, 49).  
 Briefly, the baseline sample was drawn in 1994 from government registries (greater 
Munich area, Germany); N=3,021 interviews were conducted (response rate (RR)=71%). 
The first follow-up (T1; range 1.2-2.1 years since baseline) was conducted only for the 
younger study cohort (age 14-17 at T0; N=1,228; RR=88%), whereas the second (T2, range 
2.8-4.1 years since baseline; N=2,548, RR=84%) and third follow-up (T3, range 7.3-10.6 
years since baseline; N=2,210; RR=73%) were conducted among all subjects.  
All participants provided written informed consent, except for those younger than 18 
years, in which case the parents provided written informed consent. The EDSP project and 
its family genetic supplement have been approved by the Ethics Committee of the Medical 
Faculty of the Technische Universitaet Dresden (No: EK-13811).  
 
Assessments 
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Symptoms, syndromes and diagnoses of DSM-IV mental disorders were assessed 
face-to-face by clinically trained interviewers with the computer-assisted version of the 
Munich-Composite International Diagnostic Interview (DIA-X/M-CIDI) (50). The DIA-X/M-CIDI 
is supplemented by a separate respondent’s booklet that includes disorder-specific 
questionnaires as well as symptom lists and cognitive aids to assist the respondent in 
answering complicated symptom questions and in dating symptom onset and recency (51). 
Reliability and validity was moderate to good for all the disorders covered by the DIA-X/M-
CIDI (52-54). Kappa for diagnostic test-retest reliability was 0.72 for DSM-IV SAD and 0.75 
for SAD stem items (52). Validity of the DSM-IV SAD diagnoses compared with independent 
clinical consensus diagnoses by treating physicians was estimated with a kappa of 0.80 (53). 
The intraclass coefficient for SAD age of onset was 0.70 (52). At baseline, the DIA-X/M-CIDI 
was used to assess lifetime diagnoses; follow-up assessments covered the time interval 
since the last interview. The SAD section began with a series of stem questions (“Have you 
ever had an unusually strong fear or avoidance of doing things in front of others or of being 
the centre of attention? For example, have you ever had an unusually strong fear of ...”) to 
assess the presence of strong fears regarding the following 6 social and performance 
situations (seven situations from T1 on): eating or drinking while others are watching, writing 
while others are watching, going to a meeting or party, taking an exam or interview at work or 
school although well prepared, speaking in front of others, speaking with others, and from T1 
on 'other' social fears (DSM-IV criterion A-1). To improve recall and memory, questions were 
visually accompanied with a list of these situations (51). Respondents were also asked to 
give a concrete example for each item endorsed to allow for clarification. After at least one 
social fear situation was elicited, a subsequent series of nine questions asked about anxiety 
cognitions that occur when confronted with such social fear situations (e.g. something 
embarrassing or shameful could happen, being regarded as dumb or weak, being regarded 
as crazy, to experience an anxiety (panic) attack, etc.), of which at least 1 must be endorsed 
(criterion A-2). Criterion B (exposure to social or performance situations almost invariably 
provokes an immediate anxiety response) was assessed by a list of anxiety symptoms (e.g., 
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sweating, heart racing, etc.), of which at least 2 must have occurred when thinking about or 
when being exposed to social fear situations. Respondents further indicated whether they 
considered either the anxiety or the avoidance to be excessive or unreasonable (criterion C), 
and whether they frequently avoided the situations or, if not, endured the situations with 
distress (criterion D). The clinical significance (criterion E) was assessed by determining 
whether the respondent reported that the social fears or avoidance interfered a lot with 
normal routines, whether they sought professional help for the fears, or whether they 
repeatedly used medication due to these fears. Respondents were classified as threshold 
DSM-IV SAD cases when they met criteria A to E. In contrast to an earlier study (9) but in 
line with more recent contributions (41, 55, 56), criterion E was required when respondents 
were 18 years or older (49). Taking all available information from all assessment waves into 
account, N=209/3,021 (6.6%) respondents met criteria for DSM-IV SAD. For N=156/209 
(75.3%) SAD respondents at least one subsequent follow-up assessment was available. 
Among those, mean follow-up duration was 6.9 years (range 1-10 years). The remaining 
N=53/209 cases either reported threshold SAD at the last assessment wave for the first time 
(N=29, 13.0%) or did not participate at any follow-up assessments (N=24, 11.7%). There was 
no selective drop out (attrition) from baseline to 10-year follow-up for SAD (OR=1.1, 95%CI: 
0.8-1.6). 
Besides the DSM-IV SAD diagnosis, we also considered following groups with social 
anxiety below the full diagnostic threshold for course/persistence analyses: Respondents 
were classified as subthreshold SAD cases when they met criterion A and three of the 
criteria B, C, D or E. Respondents who were not classified with (sub-)threshold SAD but 
affirmed at least one of the DIA-X/M-CIDI stem questions referring to ‘unusually strong’ fears 
in or avoidance of social and performance situations were labelled as symptomatic SAD. The 
inclusion of these broader categories accounts for previous indications of the waxing and 
waning nature of psychopathology among youth and young adults (7, 26) and the possibility 
of partial remissions (29). The differentiation of social fear expressions below the diagnostic 
threshold (i.e. symptomatic and subthreshold SAD) is further justified by prior findings on 
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increasing levels of disability and comorbidity and decreasing levels of psychosocial 
functioning within the social anxiety spectrum (5, 7). 
The combination of the symptomatic, subthreshold, and threshold cases will be 
referred to as ’at least symptomatic SAD’.  
Persistence of SAD. Persistence of SAD was defined as the proportion of years an 
individual was affected by SAD symptoms given the total number of years observed after 
initial threshold SAD onset. Using retrospective age of onset and age of recency information 
on SAD symptoms, a composite score was created: (1) Consistent with prior work (41), age 
of onset and age of recency information were aggregated across assessments, using the 
lowest reported age of onset and highest reported age of recency by convention. (2) In order 
to reduce recall bias leading to overestimation of SAD persistence, a more conservative age 
of onset convention was used: When age of onset was 10 years or lower, age of onset 
information was replaced by the age of 10. (3) Starting from the first report of initial threshold 
SAD, persistence scores were calculated irrespective of prior symptomatic or subthreshold 
SAD conditions. Persistence scores reflect the proportion of years an individual was affected 
by either threshold SAD, at least subthreshold SAD, or at least symptomatic SAD after initial 
onset of threshold SAD. The scores in the total sample range from 0 (no SAD) to 1 (SAD 
symptoms in all years observed since initial onset of threshold SAD). For example, a 
respondent aged 15 years at baseline (T0) participated at all subsequent assessment waves 
(25 years of age at T3). First onset of threshold SAD was reported at age 15, resulting in 
overall 10 years of being observed. Threshold SAD was present until age 17. From age 17 to 
21 no symptoms occurred, but from age 22 to 25 criteria for subthreshold SAD were met. 
Regarding only threshold SAD, the persistence score reflects 3 years (ages 15–17) spent 
with threshold SAD, and persistence would be 3/10, indicating that threshold SAD symptoms 
were present during 33% of the time observed. This persistence rate increases to 70%, when 
the four years (ages 22–25) of subthreshold SAD were additionally considered [(3 + 4)/10]. 
We also calculated a total persistence index that considers weights for different diagnostic 
status (symptomatic 1/3, subthreshold 2/3, threshold 1). To examine validity of the 
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persistence scores, we used more direct information on persistence as provided by the 
respondents in the M-CIDI SAD-section. Respondents were asked whether the anxiety 
and/or the avoidance of social situations persisted for months or even years and if not, 
whether this was the case because social situations were completely avoided. The sum 
score of positive responses from all assessment waves (observed range 0-4) was 
significantly correlated with the various persistence-scores (all p-values <.01), ranging for 
SAD-subjects with follow-up assessment from r = .30 (threshold level) to r = .51 (at least 
symptomatic level). 
Diagnostic stability vs. remission of SAD. Diagnostic stability and remission of 
SAD were strictly prospectively examined by using diagnostic information from follow-up 
assessments after the person met threshold SAD criteria for the first time (N=156 with “initial 
threshold SAD”); retrospective age of onset and age of recency information was not taken 
into account here. After initial threshold SAD (at T0, T1 or T2), the maximum follow-up 
diagnostic status (at T1-T3, T2-T3 or T3) was described on four levels: no SAD symptoms, 
symptomatic, subthreshold or threshold SAD. According to the diagnostic status at follow-up, 
subjects were classified as stable if criteria for at least symptomatic SAD were met, or as 
remitted if no SAD criteria were met.  
It should be noted that both approaches to describe the course of SAD do not allow a 
differentiation between recurrence and chronicity. 
 
Predictors for SAD persistence and stability. Based on the previous literature, 
several clinical characteristics of initial SAD and established vulnerability and risk factors 
were examined as putative predictors for (a) persistence and (b) stability vs. remission of 
SAD: 
Parental psychopathology (lifetime diagnoses in either mother or father: SAD; any 
other anxiety disorder including specific phobia, generalized anxiety disorder, panic disorder, 
agoraphobia; any depressive disorder including major depressive disorder or dysthymia, any 
substance use disorder including abuse or dependence of alcohol or illicit drugs) was derived 
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by aggregation of diagnostic information from direct interviews in parents (at T1/T3) and 
indirect family history information using the respondents as informants (at T0/T2/T3). 
Following examination of agreement patterns between family history report and available 
direct interviews, a priority hierarchy was determined (57): If direct information from T3 
and/or T1 was available, it was used. If no direct information was available, T3 family history 
reports were used with the highest priority, followed by T2 and T0 family history reports. 
Behavioural inhibition was measured by the Retrospective Self-Report of Inhibition 
scale (58, 59), personality measures were derived from the Tripartite Personality 
Questionnaire (60).  
SAD characteristics were derived from the DIA-X/M-CIDI SAD module. Age-of-onset 
was available for N=208 respondents and is based on the lowest age of onset reported at 
any of the assessment waves. Types of feared social situations at initial threshold SAD that 
were avoided or endured with anxiety because of doing things in front of others or because 
of being the centre of attention were: 1) eat/drink in public, 2) public writing, 3) go to a 
meeting/party, 4) tests/exams, 5) public speaking, and 6) talk to others; at T1/T2/T3 “other” 
social fears were also assessed. Because explorations of the factorial structure of social 
fears in our data did not suggest separate factors for interactional or performance fears but 
indicated a special role of test fears (56), we refrained from grouping social fears based on 
content type and separately examined the predictive role of test fears and other social fears 
both overall and in isolation (i.e. without co-occurring other social fears). However, we 
examined the role of the number of endorsed social fear situations and the generalized 
subtype as stipulated in DSM-IV defined here by the presence of 3+ feared social situations. 
Catastrophic anxiety cognitions refer to nine feared events (e.g. something embarrassing or 
shameful could happen, being regarded as dumb or weak) while being in situations or 
assuming situations that involved being the centre of attention. Degree of avoidance (1-never 
to 4-always) refers to the frequency at which social situations were avoided due to anxiety. 
As outlined above, it should be noted that not all SAD cases must reveal avoidance as they 
may also fulfill criterion C because they endured such situations with distress. Degree of 
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impairment (1-not at all to 4-very much) reflects how much anxiety or avoidance of social 
situations interfered with daily life. Again, as outlined above, not all SAD cases must reveal 
significant impairment because clinical significance (criterion E) may also be established by 
professional help seeking or medication use. Comorbid conditions were assessed using the 
respective DIA-X/M-CIDI section and included other anxiety (specific phobia, panic disorder, 
agoraphobia, generalized anxiety disorder), depressive (major depression, dysthymia), 
substance use (abuse or dependence of alcohol or illicit drugs), somatoform (hypochondrias, 
pain disorder, undifferentiated somatization disorder) and eating disorders (anorexia 
nervosa, bulimia nervosa, anorexia nervosa not otherwise specified, bulimia nervosa not 
otherwise specified) as well as panic attacks. The clinical characteristics including 
comorbidity were derived at the assessment wave when threshold SAD was reported for the 
first time and used as predictor variables for SAD course. Table 1 provides an overview of 
the distribution of the vulnerability and the initial clinical characteristics (when SAD was first 
reported) in the SAD sample. There were no significant differences between SAD 
respondents with and without follow-up assessments in these variables except that SAD 
cases with follow-up assessments reported lower ages of SAD onset and higher levels of 
behavioural inhibition (p-values<.05).  
 
-Table 1- 
 
Statistical analysis  
Results (%, ratios, coefficients) are weighted by age, gender, and geographic location 
at baseline to match the distribution of the original sampling frame (48); frequencies (N) are 
unweighted. The Stata Software package (61) was used to compute robust variances, 
confidence intervals, and p-values (by applying the Huber-White sandwich matrix) required 
when analyses were based on weighted data (62).  
Diagnostic information from the assessment waves were aggregated for cumulative 
lifetime incidences (T0/T1/T2/T3) or maximum follow-up status after initial threshold SAD 
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(T1/T2/T3, T2/T3, T3). As we were interested in an accurate picture of the natural course and 
persistence of SAD, and in order to prevent overestimation, we restricted most analyses on 
the course and persistence of SAD to subjects with at least one follow-up assessment after 
initial threshold SAD (N=156/209).  
Predictors for course of SAD were examined using univariate regression analyses. 
For associations with bivariate outcome variables (stability vs. remission), logistic regression 
analysis were used (odds ratios; OR). For dimensional outcome variables (persistence), 
linear regression analyses were conducted. Multiple regression analyses included significant 
predictors from univariate regressions and were used to identify the most powerful 
predictors. 
 
RESULTS 
Persistence of SAD 
The mean persistence for threshold SAD in the total SAD sample (N=208) was 
M=0.62 indicating that on average 62% of the observed time after initial SAD onset was 
spent with symptoms. This rate further increased when subthreshold (M=0.67) and 
symptomatic SAD (M=0.70) after initial onset of threshold SAD were additionally taken into 
account. Overall across the three threshold levels, the mean weighted persistence index was 
0.66 in the total sample and was not different in males and females (p>.8). Results also 
indicated that the persistence score decreased gradually with longer follow-up duration 
(p<.001). 
 
-Table 2- 
 
Univariate regression analyses using each of the characteristics from Table 1 as 
putative predictors for higher SAD persistence were performed separately for all SAD cases 
(N=208) and for those with follow-up assessments (N=156). Because only few differences 
were found between the total and the follow-up completer group (Table 3), and because the 
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latter may be assumed to more accurately reflect SAD persistence, we discuss the follow-up 
completer group in further detail. A higher persistence of SAD was significantly predicted by 
early age of onset of SAD, the generalized subtype, a greater number of catastrophic anxiety 
cognitions, more severe avoidance due to social fears, and more severe levels of 
impairment. Co-occurring panic attacks also predicted a greater persistence of SAD. 
Significant vulnerability factors were: parental SAD or parental depressive disorder, high 
levels of self-reported behavioural inhibition in childhood, harm avoidance and low novelty 
seeking. Multiple regression analyses, taking into account all significant variables, revealed 
the generalized subtype and high levels of harm avoidance as the most important predictors 
in the total sample; in the follow-up completer sample, a lower age of onset and more severe 
impairment were additionally found to contribute significantly to the model (p<.05). 
It is noteworthy that in the univariate analyses most individual social fear situations at 
initial threshold SAD (talking to others, going to meeting/party, public speaking, ‘other’ social 
fear) predicted persistence but only when they did not occur in isolation. One notable 
exception is social fears of exams or tests that were predictive of low SAD persistence, 
particularly if they occurred in isolation. Overall, SAD cases with fear of exams/tests revealed 
the lowest average number of social fears (2.6) among all types of social fears (mean feared 
situations: 3.0 for public speaking to 4.2 for writing). Individuals with exam/test fears also had 
the lowest probability of belonging to the generalized subtype (44.7%); risk was highest 
among individuals with fears of going to meetings/parties (82.7%). Overall, as shown in 
Table 1, fears of exams/tests occurred most frequently “in isolation” among all social fears 
(23.0%). 
 
-Table 3- 
 
Diagnostic stability and remission of SAD 
Strictly prospectively (relying on diagnostic information without consideration of age-
of-onset or age-of-recency information), the diagnostic stability rates of threshold SAD, 
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defined as meeting the full DSM-IV criteria again at a subsequent assessment, ranged 
between 7.1% and 15.1%, depending on the considered assessment times and follow-up 
periods (Table 4). Overall, among those who had threshold DSM-IV SAD for the first time up 
to T2, 15.5% revealed full criteria again during at least one subsequent follow-up wave after 
initial report of threshold SAD (Figure 1). Although the majority of SAD cases did not meet 
full DSM-IV SAD criteria again at subsequent waves, a substantial proportion still had 
subthreshold SAD (12.7-21.2%; overall: 19.7%) or at least some significant SAD symptoms 
(9.1%-25.3%; overall: 21.5%).  
Of note, although the stability rates for SAD appear numerically rather moderate, SAD 
at each time point was, compared to those without SAD, associated with a considerably 
increased risk to also have the disorder (OR: 7.1-22.1) or signs and symptoms of the 
disorder (OR=2.9-11.0) at later points in time (Table 4). If no SAD was reported during follow-
up, the presence of other disorders was probable (24.6%-35.8%; overall: 28.2%). Only 14.2-
31.5% (overall: 15.1%) of DSM-IV SAD cases were completely remitted at follow-up, i.e. they 
revealed neither SAD symptoms nor other disorders.  
We also investigated whether initial symptomatic or subthreshold SAD conditions are 
associated with follow-up SAD caseness including the development of subsequently more 
intense SAD expressions (i.e. subthreshold or full threshold SAD). Multinomial logistic 
regression analyses revealed significant findings for all time point and threshold level 
combinations (Table available upon request), indicating an overall increased probability to 
remain or progress within the SAD spectrum over time. 
 
--Table 4 and Figure 1-  
 
To examine predictors for diagnostic stability of SAD, threshold, subthreshold and 
symptomatic SAD outcomes after initial SAD diagnosis (N=156) were combined in one group 
‘at least symptomatic SAD’ (N=93) and compared to those without follow-up SAD symptoms 
('SAD remitters', N=63). The SAD-specific stability/remission rate did not differ by follow-up 
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duration or by gender (Table 5). Age of onset of SAD, however, was predictive in that lower 
ages of onset were associated with stability. Among the other clinical, comorbidity and 
vulnerability variables listed in Table 1, the generalized subtype, co-occurring panic attacks, 
childhood behavioural inhibition, and high harm avoidance were predictors of stability; a 
trend finding emerged for a higher number of catastrophic anxiety cognitions (OR=1.3, 
95%CI: 1.0-1.7, p=.052) mainly due to “something embarrassing or shameful could happen” 
and “being regarded as dumb or weak”. The generalized subtype and high harm avoidance 
were revealed as the most powerful predictors for stability in a multiple regression analysis 
(p<.05).  
 
-Table 5- 
 
DISCUSSION 
Using data from a large prospective-longitudinal community study of adolescents and 
young adults followed-up across the high risk period for SAD onset and potential subsequent 
chronicity, we complemented prior research on the incidence of SAD (9, 45) and its risk 
factors (33, 34, 40) by examining the natural course of SAD and potential clinically 
meaningful predictors. In contrast to previous investigations (e.g. 7, 18, 22-25, 29), we 
examined the course of SAD both in terms of persistence using retrospective age of onset 
and age of recency information and in terms of diagnostic stability (versus remission). This 
longitudinal approach takes into account the full range of SAD symptoms, including 
conditions above and below the diagnostic threshold. Before discussing the findings in detail, 
some limitations of our study should be noted. First, the EDSP study was not specifically 
designed and powered to study the course of SAD. The symptom and diagnostic 
assessment was exclusively based on a standardized diagnostic interview (DIA-X/M-CIDI) 
that did not include specific questions on course patterns, which impedes differentiation of 
recurrence vs. chronicity. The between-assessment intervals extended to several years and 
the number of cases with SAD and at least one follow-up assessment was limited. Second, 
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not all study participants had reached the maximum age of 34 years at the time of last follow-
up and the follow-up time period varied among SAD cases. The overall stability and 
persistence rates should therefore be considered a conservative estimate of the true rates. 
Furthermore, no conclusions can be drawn regarding the stability and persistence of SAD in 
higher ages beyond young adulthood. Third, despite the prospective-longitudinal design of 
the EDSP study, data are based on retrospective recall and thus is subject to bias which may 
have particularly influenced the persistence measure. 
 
SAD is one of the most prevalent mental disorders in the community. Our observed 
cumulative incidence rate of 6.6% for threshold SAD is in line with lifetime findings from other 
research (1-3). Also consistent with other studies (2-9), the majority of SAD cases reported a 
symptom onset in childhood or early adolescence, which indicated this developmental phase 
as the core period for targeting potential prevention and early intervention programs. There is 
particular need for such interventions, as our study impressively shows a high persistence 
and stability of symptoms particularly in early onset SAD cases. Unfortunately, treatment 
rates at this young age are particularly low (63). 
Little systematic, methodologically sound research has been conducted to 
characterize the natural course of SAD in greater detail, particularly in non-patient, 
representative samples from the community. Cross-sectional epidemiological and clinical 
studies suggest a chronic, stable and non-remitting course of the disorder (4, 5, 8, 12, 16-
22). Yet, their results rely merely on retrospective reports that may be subject to significant 
recall-bias, particularly when considering long time periods. More specifically, the frequently 
reported number of years between symptom onset and recency, in terms of a persistence 
measure, likely overestimates chronicity because symptom-free intervals are not taken into 
account.  
The findings from our multi-wave study do not fully confirm previous retrospective 
findings from cross-sectional studies that highlight a chronic, stable and non-remitting course 
of the disorder. In line with the chronicity assumption are the findings of our persistence 
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measure revealing that individuals with DSM-IV SAD suffer from SAD symptoms at least fifty 
percent of the years observed after first onset; rates were even higher when subsequent 
subthreshold and symptomatic SAD expressions were also considered. Persistence rates 
tended to be lower when the follow-up observation period after initial SAD diagnosis was 
longer, suggesting either stable remissions occurring during follow-up or the fact that 
respondents with follow-up assessments had a good chance for symptom-free periods. 
Generally, these findings indicate a potential methodological artefact arising from cross-
sectional research that suggests a very high stability and chronicity of SAD merely based on 
retrospectively recalled age of onset and age of recency information or by examining the 
ratio of lifetime to 12-month prevalence. 
This interpretation is supported by our prospective diagnostic stability findings that 
somewhat contradict the assumption of high disorder-specific chronicity. In line with other 
prospective studies in children, adolescents and young adults (7, 8, 23-27, 29), we find that 
remissions from or improvements in SAD indeed occur. Our study revealed that only 15.5% 
of DSM-IV SAD cases met the full criteria again later in the study. However, this rate 
increased to 56.7% when also considering symptomatic and subthreshold SAD, which have 
been shown to be associated with considerable disability and comorbidity and impairment in 
psychosocial functioning (5, 7, 30, 32). 
This indicates that a substantial proportion of children, adolescents and young adults 
continue to have significant SAD symptoms years after SAD initially emerged. Thus, 
supported by our association analyses showing significant associations between prior and 
subsequent expressions within the SAD spectrum, our strictly prospective findings are 
consistent with the assumption of a considerable degree of homotypic continuity, yet with an 
indication of waxing and waning SAD symptoms and oscillations around the diagnostic 
threshold as previously described for SAD (7) and other anxiety disorders as well (26). 
Moreover, even when remitting from SAD, other disorders frequently persist or develop in the 
years after, making it extremely unlikely that SAD cases turn out to be completely free of 
psychopathology over the long run (15.1%). Overall, these findings are in line with other 
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prospective research indicating both disorder-specific (7, 64-66) and more heterotypic 
longitudinal associations (7, 47, 66).  
In light of the ongoing revision process for DSM-5, this necessarily prompts the 
question of which types of SAD are associated with particular stable-persisting as opposed to 
instable and remitting courses. Our findings suggest that the generalized subtype (defined 
here as fearing three or more social situations) is a powerful predictor for a stable-persisting 
course of SAD. Thus, this subtype differentiation has predictive power in the sense of a more 
general severity indicator. Given that SAD symptoms appear to fall along a continuum of 
severity based on the number of social fears (67), a definite criterion of the number of feared 
situations required to indicate symptom severity however is unlikely (68). We also do not 
have convincing evidence for an ‘interaction’ versus ‘performance’ fear differentiation, as the 
factor structure of social fears appears unidimensional in our data. The noteworthy exception 
is social fear of exams/tests. This particular ‘performance’ fear is, particularly if occurring in 
isolation which is frequently the case, characterised by low persistence with symptom 
alleviations likely to occur when finishing school/university.  
Besides the breadth of the feared social situations, other measures of SAD symptom 
complexity and severity, such as the number of catastrophic anxiety cognitions, degree of 
avoidance and impairment, and co-occurring psychopathology, most consistently panic 
attacks, were revealed in our study as important clinical characteristics that predict a stable-
persisting course of SAD. Our findings are in line with other research (22, 42-44) suggesting 
the importance of clinical features as course-predictors for SAD and suggest that such 
diagnostic information is useful and practical to inform prognosis and need for intervention.  
In addition to clinical diagnostic measures, parental psychopathology (SAD and 
depressive disorders) and, more consistently, temperamental measures (behavioural 
inhibition, harm avoidance) were found to provide significant predictive power. Thus, such 
factors are not only associated with the risk for onset of SAD (33-37, 57, 59), but also predict 
adverse outcomes. Importantly, there are indications for complex interactions with other 
familial factors such as rearing styles (e.g. lack of emotional warmth) and dysfunctional 
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family functioning contributing to higher persistence of SAD (41). More research is necessary 
not only to improve understanding of the vulnerability and risk factors for onset of SAD, but 
also to delineate their role in course and outcome. Overall, our study suggests that familial 
and temperamental measures along with clinical diagnostic measures inform prognosis and 
thus appear useful for targeting intervention to prevent adverse long-term outcomes. Future 
research may more strongly focus on comparative analyses using different methodological 
approaches on course as there may be differential findings. 
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Characteristics
Gender
Males N, %w col 70 31.6 54 30.9 16 33.8
Females N, %w col 139 68.4 102 69.1 37 66.2
Clinical characteristics of initial SAD b 
Age at SAD onset (in years) a M, SD 13.1 5.4 12.0 4.8 16.2 6.0
<=11 N, %w col 85 40.1 73 45.5 12 23.2
12-14 N, %w col 65 27.4 51 29.3 14 21.5
>=15 N, %w col 58 32.5 32 24.2 26 55.3
Feared social situation
- talking to others N, %w col 69 36.6 56 38.2 13 31.6
- going to a meeting or party N, %w col 57 32.8 40 29.0 17 40.2
- eating or drinking in public N, %w col 45 23.4 36 23.4 9 23.3
- exams or tests N, %w col 131 62.7 100 64.3 31 61.7
- public speaking N, %w col 118 57.9 89 57.6 29 58.8
- writing in public N, %w col 16 9.2 11 8.2 5 12.1
- other c N, %w col 24 12.3 11 7.3 13 27.7
Number of feared social situations M, SD 2.3 1.5 2.3 1.4 2.6 1.7
1 N, %w col 93 41.2 67 41.1 26 41.5
2 N, %w col 46 22.3 37 24.7 9 15.1
3+ (~ generalized subtype) N, %w col 70 36.5 52 34.3 18 43.4
Isolated social fears
- talking to others N, %w col 9 4.3 6 3.1 3 4.1
- going to a meeting or party N, %w col 10 4.4 5 3.4 5 7.4
- eating or drinking in public N, %w col 7 3.6 5 3.8 2 3.1
- exams or tests N, %w col 52 23.0 39 23.7 13 20.9
- public speaking N, %w col 29 12.2 20 11.9 9 13.1
- writing in public N, %w col 5 2.7 4 3.2 1 1.0
- other c N, %w col 3 1.3 2 1.4 1 1.0
Anxiety cognitions
- something embarrassing or shameful could happen N, %w col 103 49.8 90 57.2 13 27.1
- being regarded as dumb or weak N, %w col 102 52.1 89 60.1 12 27.7
- being regarded as crazy N, %w col 17 9.3 13 8.9 3 10.4
- experience an anxiety (panic) attack N, %w col 43 22.6 35 24.5 8 17.0
- to be confused N, %w col 129 63.9 112 36.4 17 72.8
- to be ashamed N, %w col 79 40.6 66 44.8 13 27.8
- to throw up N, %w col 12 8.7 11 10.8 1 2.2
- to loose control over intestinal organs N, %w col 5 2.8 5 3.7 0 0.0
- to turn red N, %w col 97 44.7 84 51.2 13 25.0
Number of anxiety cognitions (1-9) M, SD 3.4 1.6 3.3 1.5 3.6 1.8
Severity measures
Level of avoidance (1-4) M, SD 2.2 1.1 2.2 1.0 2.2 1.2
Level of impairment (1-4) M, SD 2.7 0.9 2.6 0.9 2.8 1.0
Comorbidity at time of initital SAD g
panic attacks N, %w col 25 15.0 17 13.5 8 19.3
anxiety disorder h N, %w col 76 38.3 52 35.9 24 45.6
depressive disorder i N, %w col 60 33.9 41 31.8 19 40.4
substance use disorder k N, %w col 52 26.6 33 23.7 19 35.6
somatoform disorder l N, %w col 30 15.1 19 13.6 11 19.7
eating disorder m N, %w col 11 6.8 9 7.5 2 4.4
Parental psychopathology 
SAD N, %w col 22 9.3 19 10.3 3 6.4
other anxiety disorder h N, %w col 97 44.9 73 44.9 24 45.1
depressive disorder i N, %w col 80 39.5 56 37.8 24 44.6
substance use disorder k N, %w col 37 19.3 30 19.4 7 19.1
Temperament/personality
behavioral inhibition (total sum) n M, SD 2.4 0.5 2.5 0.5 2.2 0.4
behavioral inhibition (social fear) n M, SD 2.7 0.7 2.8 0.7 2.5 0.6
behavioral inhibition (illness fear) n M, SD 2.2 0.6 2.3 0.7 1.9 0.5
novelty seeking o M, SD 16.4 5.2 16.0 5.2 17.9 4.8
harm avoidance o M, SD 17.3 7.0  17.1 7.1 18.6 6.5
reward dependence o M, SD 18.1 4.7 18.0 4.7 18.6 4.8
Note: SAD Social Anxiety Disorder, N unweighted number; %w percent weighted; M mean weighted; SD standard deviation
a no age of onset available for N=1 (male; no follow-up assessment)
b derived from DIA-X/M-CIDI SAD section when SAD was first reported
c only assessed at T1, T2, T3
g derived from respective DIA-X/M-CIDI section at time when SAD was first reported
h includes specific disorder, generalized anxiety disorder, panic disorder, agoraphobia 
i includes MDE, dysthymia 
k includes alcohol and ill. drug abuse or dependence
l includes hypochondrias, pain disorder, undifferentiated somatization disorder
m  includes anorexia nervosa, bulimia nervosa, anorexia nervosa NOS, bulimia nervosa NOS
n  from Retrospective Self-Report of Inhibition (RSRI)
o  from Tridimensional Personality Questionaire (TPQ)
SAD
Table 1: Characteristics of SAD cases
total 
(N = 209)
with follow-up       
(N = 156)
without follow-up 
(N = 53)
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Table 2: Persistence of initial full SAD by age of onset and Follow-up duration 
Persistence Scores a N M SD N M SD N M SD
threshold level 208 0.62 0.28 156 0.54 0.25 52 0.89 0.22
at least subthreshold level 208 0.67 0.29 156 0.59 0.24 52 0.89 0.22
at least symptomatic level 208 0.70 0.28 156 0.64 0.27 52 0.89 0.22
Index b
  total 208 0.66 0.27 156 0.59 0.25 52 0.89 0.22
  by follow-up duration
none (1 wave only) - - 52 0.89 0.22
1 to 4 years - 29 0.71 0.22 -
5 to 8 years - 83 0.60 0.22 -
9 or 10 years - 44 0.50 0.27 -
by gender
males 69 0.68 0.28 54 0.59 0.24 15 0.93 0.22
females 139 0.66 0.27 102 0.59 0.25 37 0.88 0.23
by clinical characteristics (initial SAD) c
Age of onset of SAD
<=11 85 0.69 0.22 73 0.65 0.19 12 0.92 0.26
12-14 65 0.68 0.26 51 0.61 0.23 14 0.98 0.07
>=15 58 0.62 0.34 32 0.45 0.30 26 0.85 0.24
Subtype
non-generalized 138 0.61 0.28 104 0.53 0.25 34 0.88 0.22
generalized 70 0.76 0.23 52 0.70 0.20 18 0.92 0.23
c derived from DIA-X/M-CIDI SAD section when SAD was first reported
b Persistence Index: weighted for different diagnostic status (symptomatic 1/3, subthreshold 2/3, threshold 1). 
a Persistence: proportion of years an individual was affected by SAD symptoms given the total number of years observed after initial threshold 
SAD onset. Persistence was calculated for N = 208 because for N = 1 no age of onset was available. 
Note: SAD Social Anxiety Disorder, N observed number (unweighted),  M mean,  SD  standard deviation
Persistence of initial threshold SAD
total initial threshold SAD, no follow-up
initial threshold SAD 
with at least one 
follow-up
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Table 3: Predictors of persistence of initial threshold SAD
Putative predictors Beta T P Beta T P
Clinical characteristics (initial SAD) b
Age at SAD onset (in years, dimensional) -0.1 -1.4 .162 -0.4 -5.1 <.001 §**
Feared social situations
- talking to others 0.1 1.8 .077 0.2 2.5 .013
- going to a meeting or party 0.3 4.5 <.001 0.3 3.6 <.001
- exams or tests -0.2 -2.4 <.001 -0.1 -1.5 .133
- public speaking 0.3 4.1 <.001 0.4 4.4 <.001
- other c 0.3 4.3 <.001 0.2 2.7 .007
- isolated fear of exams or tests -0.3 -5.2 <.001 -0.4 -5.1 <.001
Generalized subtype (3+ vs. 1-2 situations) 0.3 4.2 <.001 §** 0.3 4.1 <.001 §**
Catastrophic anxiety cognitions
- something embarrassing or shameful could happen 0.0 -0.1 .887 0.2 2.1 .038
- being regarded as dumb or weak 0.0 -0.2 .861 0.2 2.3 .026
- to turn red 0.0 -0.3 .765 0.2 2.1 .037
A higher number of anxiety cognitions (1-9, dimensional) 0.2 2.9 .004 § 0.2 2.6 .010 §
Severity measures
More severe avoidance (1-4, dimensional) 0.3 3.5 .001 § 0.3 3.0 .003 §*
More severe impairment (1-4, dimensional) 0.2 2.5 .013 § 0.2 2.7 .008 §**
Comorbidity at time of initital SAD g
panic attacks 0.2 3.8 <.001 § 0.2 2.8 .006 §
anxiety disorder h 0.2 2.6 .010 § 0.1 1.7 .098
depressive disorder i 0.2 2.0 .049 § 0.1 0.9 .369
Parental psychopathology 
SAD 0.0 0.7 .516 0.2 2.5 .016 §
depressive disorder i 0.1 1.3 .186 0.2 2.1 .037 §*
Temperament/personality
behavioral inhibition (total sum) n 0.2 2.4 .016 0.4 4.6 <.001
behavioral inhibition (social fear) n 0.2 2.5 .014 § 0.3 4.1 <.001 §
behavioral inhibition (illness fear) n 0.1 1.2 .228 0.2 2.7 .008 §
novelty seeking o -0.1 -1.4 .172 -0.2 -2.3 .025 §
harm avoidance o 0.4 4.3 <.001 §** 0.4 4.8 <.001 §**
b derived from DIA-X/M-CIDI SAD section when SAD was first reported
c only assessed at T1, T2, T3
g derived from respective DIA-X/M-CIDI section at time when SAD was first reported
h includes specific disorder, generalized anxiety disorder, panic disorder, agoraphobia 
i includes MDE, dysthymia 
n  from Retrospective Self-Report of Inhibition (RSRI)
o  from Tridimensional Personality Questionaire (TPQ)
§ Variable entered in multiple regression analysis, ** p<.05, * p<.1
SAD
Note: SAD Social Anxiety Disorder, Beta = standardized regression coefficient from univariate regression analyses, adjusted for age
a persistence index weighted for symptomatic (1/3), subthreshold (2/3) and threshold SAD (1) at follow-up assessment; calculated for 
N=208 because no age of onset information available for n = 1 (case without follow-up assessment after SAD diagnosis)
total 
(N = 208)
with follow-up 
assessment             
(N = 156)
Persistence (Index) a
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Table 4: Diagnostic stability of threshold SAD - longitudinal associations
No SAD symptoms 
and no other disorder
% (Ref b) OR c P % (Ref b) OR c P % (Ref b) OR c P % (Ref b) OR c P % (Ref b)
T0 (N=114) ==> T1/2 7.1 (1.9) 7.1 2.9 - 17.3 <.001 19.2 (8.6) 4.3 2.3 - 8.1 <.001 25.3 (14.5) 3.6 2.0 - 6.6 <.001 24.6 (27.8) 1.8 1.0 - 3.4  .069 23.8 (47.1)
T0 (N=97) ==> T3 12.0 (1.4) 15.2 6.5 - 35.5 <.001 12.7 (5.2) 4.1 1.9 - 8.7 <.001 9.1 (5.8) 2.9 1.3 - 6.5 .009 34.8 (28.6) 2.5 1.4 - 4.5  .003 31.5 (58.9)
T0 (N=118) ==>  T1/2/3 15.1 (2.8) 13.7 6.2 - 30.0 <.001 21.2 (10.6) 5.1 2.5 - 10.3 <.001 21.5 (15.9) 3.7 1.8 - 7.5 <.001 28.0 (32.4) 2.4 1.2 - 4.7 .015 14.2 (38.3)
T1/2 (N=40) ==> T3 12.3 (1.6) 22.1 6.5 - 75.6 <.001 12.8 (4.9) 7.5 2.3 - 25.0 .001 20.6 (5.8) 11.0 3.3 - 36.6 <.001 35.8 (28.3) 4.2 1.5 - 11.4 .005 18.5 (59.4)
b Ref: Percentage in Reference group consisting of individuals without prior threshold SAD 
Assessment times:
Threshold 
SAD      ==>   Outcome
Note: SAD Social Anxiety Disorder, T0 Baseline, T1 first follow-up, T2 second follow-up, T3 third follow-up
c OR: Odds Ratio from multinomial logistic regression, Reference group: no prior threshold SAD
Threshold SAD Subthreshold SAD Symptomatic SAD
No SAD symptoms 
but other disorder 
Outcome at follow-up a
95% CI 95% CI 95% CI 95% CI
a Hirarchical and mutually exclusive groups: Threshold SAD, if not, subthreshold SAD, if not, symptomatic SAD, if not, other disorder (includes other anxiety, depressive, substance use, somatoform and eating 
di d )
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Initial SAD b
OR P
Total N, %w row 63 43.3 93 56.7 -
Follow-up duration (in years) M, SD 7.0 2.3 6.9 2.3 1.1 0.9 - 1.3 .478
1 to 4 N, %w row 15 49.0 14 51.0 Ref.
5 to 8 N, %w row 29 34.7 54 65.3 0.7 0.2 - 2.4 .561
9 or 10 N, %w row 19 53.7 25 46.3 1.9 0.8 - 4.3 .135
Gender
males N, %w row 21 43.5 33 56.5 Ref.
females N, %w row 42 43.1 60 56.9 1.1 0.5 - 2.4 .768
Clinical characteristics (initial SAD) c
Age of onset of SAD (in years) M, SD 13.2 5.3 11.1 4.2 0.9 0.8 - 1.0 .032 §
<=11 N, %w row 25 37.6 48 62.4 Ref.
12-14 N, %w row 20 38.0 31 62.0 0.9 0.4 2.1 .793
>=15 N, %w row 18 59.6 14 40.4 0.4 0.2 1.1 .087
Subtype
non-generalized N, %w row 50 51.0 54 49.0 Ref.
generalized N, %w row 13 28.3 39 71.7 2.9 1.2 - 6.8 .014 §**
Catastrophic anxiety cognitions
something embarrassing or shameful 
could happen
no N, %w row 37 56.1 29 43.3 Ref.
yes N, %w row 26 33.2 64 66.8 2.8 1.3 - 6.1 .008 §
being regarded as dumb or weak
no N, %w row 34 53.8 33 43.2 Ref.
yes N, %w row 29 26.2 60 63.8 2.3 1.1 - 4.7 .029 §
Number of anxiety cognitions (1-9 
dimensional) M, SD 3.1 1.5 3.6 1.5 1.3 1.0 - 1.7 .052
Comorbidity at time of initital SAD g
no co-occurring panic attacks N, %w row 60 47.6 79 52.43 Ref.
co-occurring panic attacks N, %w row 3 15.7 14 84.29 5.4 1.3 - 22.1 .020 §
Temperament/personality
behavioral inhibition (total sum) n M, SD 2.4 0.4 2.6 0.5 1.4 1.1 - 1.9 .013
behavioral inhibition (social fear) n M, SD 2.6 0.7 2.9 0.7 1.4 1.0 - 1.8 .021 §
harm avoidance o M, SD 15.1 6.3 18.4 7.3 1.1 1.0 - 1.1 .025 §**
g derived from respective DIA-X/M-CIDI section at time when SAD was first reported
n  from Retrospective Self-Report of Inhibition (RSRI)
o  from Tridimensional Personality Questionaire (TPQ)
§ Variable entered in multiple regression analysis, ** p<.05, * p<.1
b first SAD diagnosis at T0, T1 or T2 and at least 1subsequent follow-up available (N=156)
Table 5: Diagnostic stability of SAD by various characteristics
Follow-up a
95%CI
a cumulated across available assessment waves after initial threshold SAD diagnosis (n = 156/209 SAD cases, for n = 53 no follow-up status was available due 
to drop out or first diagnosis of threshold SAD at T3)
no SAD 
at least 
symptomatic 
SAD 
Associations
Corresponding author: Katja Beesdo-Baum 
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Figure 1: Diagnostic stability and remission of DSM-IV SAD: Conditional probability for 
diagnostic status at follow-up (T1, T2, and/or T3) among those with initial thresold DSM-IV 
SAD diagnosis (at T0, T1 or T2) (N=156). 
 
 
 
 
